How Sweet Were Nektar Therapeutics' Q3 Results?
Nektar Therapeutics (NASDAQ: NKTR) hasn't left a sweet taste in investors' mouths so far in 2019. The stock has dropped nearly 44% year to date, with most of this decline coming after the biotech reported manufacturing issues with two batches of experimental drug bempegaldesleukin (also referred to as bempeg).
But investors had reasons to like Nektar's third-quarter results, announced after the market closed on Wednesday. Here are the highlights of the company's Q3 update.
Image Source: Getty Images.
Source Fool.com
